The case for investing in young scientists

When he was just 27 years old, Adrian Krainer was offered the opportunity to run his own lab at CSHL. Research by his team has led to the development of what promises to be the first drug therapy for spinal muscular atrophy, a motor-neuron disease that cripples and kills the very young. Read more.